187 related articles for article (PubMed ID: 29133048)
1. Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.
Yang J; Chen K; Zhang G; Yang QY; Li YS; Huang SZ; Wang YL; Yang W; Jiang XJ; Yan HX; Zhu JQ; Xiang R; Luo YF; Li WM; Wei YQ; Li LL; Yang SY
Eur J Med Chem; 2018 Jan; 143():1148-1164. PubMed ID: 29133048
[TBL] [Abstract][Full Text] [Related]
2. Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
La Pietra V; Sartini S; Botta L; Antonelli A; Ferrari SM; Fallahi P; Moriconi A; Coviello V; Quattrini L; Ke YY; Hsing-Pang H; Da Settimo F; Novellino E; La Motta C; Marinelli L
Eur J Med Chem; 2018 Apr; 150():491-505. PubMed ID: 29549836
[TBL] [Abstract][Full Text] [Related]
3. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S; Wu H; Wang J; Qiu Q
Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
[TBL] [Abstract][Full Text] [Related]
4. BAY 43-9006 inhibition of oncogenic RET mutants.
Carlomagno F; Anaganti S; Guida T; Salvatore G; Troncone G; Wilhelm SM; Santoro M
J Natl Cancer Inst; 2006 Mar; 98(5):326-34. PubMed ID: 16507829
[TBL] [Abstract][Full Text] [Related]
5. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
Li X; Su J; Yang Y; Lian W; Deng Z; Yang Z; Chen G; Zhang B; Dong C; Liu X; Li L; Wang Z; Hu Z; Xu Q; Deng X
Eur J Med Chem; 2020 Dec; 207():112755. PubMed ID: 32882611
[TBL] [Abstract][Full Text] [Related]
7. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
[TBL] [Abstract][Full Text] [Related]
8. Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.
Chen CT; Hsu JT; Lin WH; Lu CT; Yen SC; Hsu T; Huang YL; Song JS; Chen CH; Chou LH; Yen KJ; Chen CP; Kuo PC; Huang CL; Liu HE; Chao YS; Yeh TK; Jiaang WT
Eur J Med Chem; 2015 Jul; 100():151-61. PubMed ID: 26081023
[TBL] [Abstract][Full Text] [Related]
9. A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants.
Yoon H; Kwak Y; Choi S; Cho H; Kim ND; Sim T
J Med Chem; 2016 Jan; 59(1):358-73. PubMed ID: 26652860
[TBL] [Abstract][Full Text] [Related]
10. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.
Kumarasamy VM; Sun D
Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409
[TBL] [Abstract][Full Text] [Related]
11. Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma.
Wang M; Naganna N; Sintim HO
Bioorg Chem; 2019 Sep; 90():103052. PubMed ID: 31226468
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
[TBL] [Abstract][Full Text] [Related]
13. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
[TBL] [Abstract][Full Text] [Related]
14. From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
Zhang CH; Chen K; Jiao Y; Li LL; Li YP; Zhang RJ; Zheng MW; Zhong L; Huang SZ; Song CL; Lin WT; Yang J; Xiang R; Peng B; Han JH; Lu GW; Wei YQ; Yang SY
J Med Chem; 2016 Nov; 59(21):9788-9805. PubMed ID: 27739679
[TBL] [Abstract][Full Text] [Related]
15. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
16. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6
Pan S; Zhang L; Luo X; Nan J; Yang W; Bin H; Li Y; Huang Q; Wang T; Pan Z; Mu B; Wang F; Tian C; Liu Y; Li L; Yang S
J Med Chem; 2022 Feb; 65(3):2035-2058. PubMed ID: 35080890
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.
Yoon H; Shin I; Nam Y; Kim ND; Lee KB; Sim T
Eur J Med Chem; 2017 Jan; 125():1145-1155. PubMed ID: 27814560
[TBL] [Abstract][Full Text] [Related]
18. Discovery of
Mologni L; Dalla Via M; Chilin A; Palumbo M; Marzaro G
ChemMedChem; 2017 Aug; 12(16):1390-1398. PubMed ID: 28639308
[TBL] [Abstract][Full Text] [Related]
19. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
Akeno-Stuart N; Croyle M; Knauf JA; Malaguarnera R; Vitagliano D; Santoro M; Stephan C; Grosios K; Wartmann M; Cozens R; Caravatti G; Fabbro D; Lane HA; Fagin JA
Cancer Res; 2007 Jul; 67(14):6956-64. PubMed ID: 17638907
[TBL] [Abstract][Full Text] [Related]
20. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
